Background: The goal of therapy in Chronic Myeloid Leukaemia (CML) with tyrosine kinase inhibitors (TKIs) has been to achieve the molecular responses, as measured by the reduction or elimination of BCR-ABLl transcript. Objective: The aim of the study is to observe the molecular response status of CML patients to TKIs. Methodology: This is an observational study and was conducted in the department of Haematology, Bangabandhu Sheikh Mujib Medical University (BSMMU) from February 2018 to January 2019. A total of 30 diagnosed CML patients on TKIs therapy was checked for quantitative BCR-ABL1 (by qRT-PCR) level. The laboratory monitoring of BCR-ABL1 RNA with RQ-PCR was likely become the model for successful molecular diagnostic monitoring of CML patients to both assess and prognosticate the efficacy of these targeted treatments. Result: Among 30 diagnosed CML patients, the mean age was found 36.1±11.7 years with range from 20 to 70 years. Males were predominant 19 (63.3%), male: female ratio was 1.7:1. Almost two third (63.3%) patients were found optimal (?10%) after 3-month BCR ABL. Age, sex, religion, marital status, occupational status, BMI, monthly income, number of family member, symptoms and sings were not statistically significant (p>0.05) when compared between BCR ABL optimal (?10%) and warning (>10%) group. Mean haemoglobin, total leukocyte count, platelet count, basophil, myelocyte and baseline BCR ABL1 were not statistically significant (p>0.05) however atypical cells was found statistically significant (p
Background: Transfusion of blood products is one of the principle components of supportive management in patients with acute leukaemia. Objective: The purpose of this study was to observe the pattern of adverse transfusion reactions (ATR) in acute leukaemia patients receiving blood component therapy. Methodology: This observational study was conducted in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from January 2018 to December 2018. Total ninety-five diagnosed case of Acute Myeloid Leukaemia (AML) and Acute Lymphoblastic Leukaemia (ALL) patients were selected for the study. Results: Four types of transfusion reactions including Febrile Non-Haemolytic Transfusion Reaction (FNHTR), Allergic, Anaphylactic, Delayed Haemolytic Transfusion Reaction (DHTR) were detected by clinical observations and relevant laboratory investigations. In this study, 25 (26.3%) patients showed different types of adverse transfusion reactions. Allergic reactions (48%) found to be the most common followed by FNHTR (32%), anaphylactic reactions (16%) and DHTR (4%). Allergic reactions (58.34%) were predominant in platelet transfusion and febrile reactions (62.5%) observed in red cell concentrate (RCC) transfusion. Urticaria, pruritus, angioedema, breathlessness, stridor, shivering, hypotension were prominent symptoms in allergic and anaphylactic reactions. On the other hand, fever, chills and rigors were prominent symptoms in case of febrile non haemolytic transfusion reaction. In our study no association between transfusion reaction with age, sex, types of donor, types of platelet and unit of transfusion was found. ATRs are mostly non-severe but rarely cause severe transfusion reaction. Conclusion: For safe blood transfusion close monitoring of transfusion, early recognition of pattern of reaction and prompt action may decrease transfusion related adverse events.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.